Glucofage

Quick links to important sections

Glucofage

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Glucofage

Quick Facts

Property Description
Active ingredient Metformin Hydrochloride
Form Oral Tablet (Immediate and Extended-Release), Oral Solution
Pharmacological class Biguanide (Antihyperglycemic Agent)
Common use Management of Type 2 Diabetes Mellitus
Origin Synthetic compound

Glucofage is a widely prescribed prescription-only oral medication used to help individuals with Type 2 Diabetes Mellitus achieve better glycemic control. It is historically significant, being the original Metformin brand introduced into the European market, and is clinically recognized for its long history of use and extensive safety data, having been continuously studied for over 60 years.


Unique Identity and Classification of Glucofage

Glucofage is a brand name whose active ingredient is the synthetic compound Metformin Hydrochloride. It is classified under the pharmacological class of biguanides, a group of antihyperglycemic agents that distinguishes it from other diabetes medications like sulfonylureas. The original brand was manufactured by Merck Sante, establishing its status as the metformin originator in many global markets.

Its unique positioning is further defined by its specific pharmaceutical preparations, which include the standard immediate-release tablet and the Extended-Release Tablet (Glucophage XR). The Extended-Release form offers the patient a convenient once-daily oral route of administration, which may improve adherence and tolerability compared to the immediate-release form.

Forms and Basic Purpose of the Antidiabetic Agent

The primary therapeutic purpose of Glucofage is to lower and stabilize elevated blood sugar levels. It is designated a first-line pharmacotherapy due to evidence gathered through decades of clinical use. This reflects that the medical community recognizes Metformin as the foundational therapy for managing this condition.

It achieves this fundamental goal through physiological actions that do not directly stimulate insulin release, focusing instead on decreasing the production of glucose by the liver and improving the sensitivity of muscle cells to insulin. This means the drug helps keep blood sugar steady by controlling both the supply and use of sugar in the body.

Regulatory References

  1. MedlinePlus Metformin Drug Information

What side effects are possible with Glucofage?

Glucofage (Metformin): Possible Side Effects and Safety Information

Glucofage (metformin hydrochloride) is generally well-tolerated, but like all medications, it can cause side effects. Understanding these effects is crucial for patient safety. Side effects are typically categorized by frequency.


Common Side Effects

These gastrointestinal issues are the most frequent, particularly when starting treatment, and often decrease over time. Taking Glucofage with meals can help minimize these symptoms.

Side Effect Note
Nausea and Vomiting May lessen after an adjustment period.
Diarrhea A very common initial effect.
Abdominal Pain Mild discomfort or cramping.
Loss of Appetite Generally temporary.

Less Common, but Serious Side Effect: Lactic Acidosis

Though rare, lactic acidosis is the most serious potential complication of metformin use. It is a medical emergency caused by a buildup of lactic acid in the bloodstream. Symptoms include severe fatigue, muscle pain, difficulty breathing, unusual sleepiness, and a slowed or irregular heart rate. Factors that increase the risk include kidney impairment, excessive alcohol intake, heart failure, and dehydration.


Other Safety Considerations

Long-term use of Glucofage has been associated with a decrease in vitamin B12 levels, which may require supplementation. Patients should discuss all pre-existing conditions, especially kidney or liver problems, and current medications with their healthcare provider before starting Glucofage. Metformin treatment should be temporarily discontinued before and for a short time after receiving iodinated contrast for imaging procedures.

Overdose and Emergency Response

Overdose and When to Seek Help

The most serious and potentially life-threatening complication documented in regulatory labeling following Glucofage overdose or significant drug accumulation is Lactic Acidosis, which is formally classified as a medical emergency. This condition may present initially with nonspecific signs, including generalized malaise, myalgias (muscle pain), increasing somnolence (drowsiness), and abdominal distress. As the condition progresses, documented severe manifestations may include hypothermia, hypotension (low blood pressure), and potentially coma.

When to Seek Immediate Medical Attention

Upon the suspicion of Lactic Acidosis or an overdose, the medication must be immediately discontinued. The official regulatory guidance is to seek immediate medical attention or contact emergency services immediately, as the condition is fatal in a significant number of documented cases. Regulatory documents explicitly state that the risk of Lactic Acidosis is amplified in patients with significant renal dysfunction or advanced age.

Management Overview

Management of metformin overdose and resulting Lactic Acidosis requires treatment in a hospital setting. The regulatory labeling confirms that no specific antidote is known or available. Therefore, the required procedural measure for managing the accumulation is prompt hemodialysis, which is utilized to efficiently remove the drug from the bloodstream and correct the underlying acidosis.

Therapeutic Uses of Glucofage

Quick Facts: Therapeutic Domain

  • Primary Use: Supports the improvement of blood sugar management in type 2 diabetes.
  • Role: Used as an initial treatment alongside lifestyle modifications.
  • Pediatric Use: Indicated to support glycemic control in children 10 years of age and older with type 2 diabetes.

Glucofage (metformin) is indicated as an adjunct to diet and exercise to support and improve blood sugar control in adults who have type 2 diabetes mellitus. It is considered a cornerstone in the initial pharmacological management of this condition. The medication is intended to assist the body in regulating its glucose levels as part of a comprehensive treatment plan that includes appropriate eating and physical activity.

For children and adolescents aged 10 years and older, this treatment is also indicated to support glycemic control in the context of type 2 diabetes. The use of this drug is a recognized component of managing high blood sugar levels associated with this form of diabetes. The primary goal of treatment is to improve long-term metabolic markers such as hemoglobin A1c levels.

Healthcare professionals often recommend Glucofage as a first-line option to help patients achieve and maintain target blood sugar ranges.

Eligibility and Restrictions for Use

Who Can and Cannot Use Glucofage? (Metformin)

Official regulatory information defines the eligibility for Glucofage use based on age, organ function, and specific metabolic states.

Eligibility Scope

Classification Eligibility Statement (Regulatory Basis)
Approved Use Approved for use in adults and children ge 10 years of age with Type 2 Diabetes Mellitus.
Absolute Contraindication Contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m^2) or acute/chronic metabolic acidosis, including diabetic ketoacidosis.
Restricted Use Initiation is not recommended for patients with moderate renal impairment (eGFR 30 to 45 mL/min/1.73 m^2). Therapy must be avoided in cases of hepatic impairment.

Population-Specific Restrictions

Older Adults (ge 65 years) require more frequent renal function assessment due to the risk of reduced kidney function. The medicine must be temporarily discontinued before or at the time of procedures like iodinated contrast imaging or major surgery that may compromise renal function. Glucofage is not indicated for Type 1 Diabetes Mellitus. For premenopausal females, regulatory labeling advises on the potential for unintended pregnancy. The decision to use during lactation requires weighing potential benefits versus documented risks, as the medicine passes into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Glucofage (metformin) interaction patterns are officially defined by its reliance on renal clearance, which structures the risk of drug accumulation and associated complications. The profile is organized around pharmacokinetic (PK) and pharmacodynamic (PD) effects documented in regulatory labeling.

Category Official Regulatory Information
Specific Interacting Medicines Iodinated Contrast Agents; Cimetidine, Ranolazine, Dolutegravir; Carbonic Anhydrase Inhibitors (e.g., Topiramate, Acetazolamide).
Mechanistic Basis Inhibition of renal tubular secretion (via OCT2/MATE transporters) resulting in increased Metformin plasma exposure; Potentiation of non-anion gap metabolic acidosis.
Interaction-Related Restrictions Iodinated Contrast Agents are a contraindicated combination in specific patient populations due to the risk of acute renal function alteration, Metformin accumulation, and lactic acidosis.
Timing-Based Rules Metformin must be temporarily discontinued at the time of, or prior to, procedures using Iodinated Contrast Agents and withheld for at least 48 hours subsequent to the procedure.
Substance Interactions Excessive Alcohol/Ethanol intake is officially documented to potentiate the effect of Metformin on lactate metabolism, increasing the risk of lactic acidosis. Immediate-release Metformin peak concentration and exposure are reduced when taken with food.
PD Interactions Co-administration with other hypoglycemic agents (e.g., Insulin) creates an additive effect, increasing the risk of hypoglycemia. Drugs that cause loss of glycemic control (e.g., Corticosteroids) can antagonize the blood sugar-lowering effect.

Connection to the overall interaction profile:

The regulatory documents establish that the drug's interaction structure centers on its vulnerability to drugs and conditions that compromise kidney function or lactate metabolism. Co-administration with key renal transporter inhibitors (Cimetidine, Ranolazine) is officially documented to increase Metformin exposure. The remaining interactions involve standard pharmacodynamic or metabolic effects that either reinforce the drug’s primary action or raise the formal risk of lactic acidosis.

Mechanism of Action

Glucofage (Metformin) modulates glucose regulation through a multi-faceted pharmacodynamic mechanism, primarily targeting the liver (hepatocytes). The molecule induces a mild inhibition of the Mitochondrial Respiratory Chain Complex I, leading to a functional shift in the cellular energy ratio ( AMP/ ATP). This altered state results in the indirect activation of AMP-Activated Protein Kinase (AMPK), which serves as a central metabolic sensor.

AMPK activation initiates a phosphorylation cascade that deactivates key enzymes required for the liver's production of new glucose, such as PEPCK and G6Pase. This action effectively suppresses hepatic gluconeogenesis, leading to a change in the amount of glucose released into the bloodstream. Beyond the liver, the mechanism also results in improved responsiveness to insulin in peripheral tissues, particularly skeletal muscle, increasing glucose utilization without necessitating higher insulin secretion.

Dosage and Administration Information

Glucofage (metformin hydrochloride) is an oral medication used to improve glycemic control in adults and children 10 years of age and older with type 2 diabetes mellitus, as an adjunct to diet and exercise. It is essential to take this medication exactly as prescribed by your healthcare provider.

General Administration Guidelines

Formulation Key Instruction Dosing Maximum Daily Dose (Adults)
Immediate-Release (Glucofage) Take with meals to reduce gastrointestinal side effects. Typically started at 500 mg twice daily or 850 mg once daily. 2550 mg (in divided doses).
Extended-Release (Glucofage XR) Swallow tablets whole. Do not crush, cut, or chew. Take with the evening meal. Typically started at 500 mg once daily. 2000 mg once daily.

Dosages are typically increased gradually in weekly or bi-weekly increments by a healthcare provider to achieve adequate blood sugar control and minimize adverse effects, as outlined in the prescribing information.

Important Precautions

Kidney Function: Because Glucofage is eliminated by the kidneys, your healthcare provider will assess your Estimated Glomerular Filtration Rate (eGFR) before starting treatment and periodically thereafter. The medication is contraindicated in patients with severe renal impairment (eGFR below 30 mL/minute/1.73 m^2).

Medical Procedures: Glucofage should be temporarily discontinued at the time of, or prior to, any iodinated contrast imaging procedure (like a CT scan) in certain patients. Your doctor will instruct you on when to stop and restart the medication after assessing your renal function.

Missed Dose: If you miss a dose, take it as soon as you remember unless it is almost time for your next dose; in that case, skip the missed dose and resume your regular schedule. Do not take a double dose to make up for a missed one.

Recent Clinical Evidence

Evidence for Blood Sugar Management in Adults

Clinical research evaluating the medicine was studied for Type 2 Diabetes Mellitus through numerous Randomized Controlled Trials (RCTs) and systematic reviews. Research primarily examined outcomes related to shifts in blood sugar markers, comparing the medicine to a placebo or other agents. Key physical measurements monitored in these short-term studies (typically 12 to 29 weeks) were changes in Glycated Hemoglobin (HbA1c) and Fasting Plasma Glucose (FPG) levels. Research describes patterns where shifts in these levels were observed, sometimes noted alongside stabilization or specific changes measured in body weight.


Research on Long-Term Health Outcomes

Long-term effects on major health outcomes were explored using a seminal Randomized Controlled Trial (RCT) that ran for approximately 10 years, followed by extended post-trial observational monitoring. The outcomes monitored included major clinical events, such as all-cause mortality, the incidence of myocardial infarction (heart attack), and stroke. Reports from the trial and its extended follow-up described patterns of observed differences in the frequency of these events when compared to the control group.

Long-Term Data in Overweight Adult Subgroups

The key long-term research on these health outcomes is derived from a large, pre-defined subgroup of overweight adults with newly diagnosed T2DM who were studied in that specific trial. Findings related to these outcomes apply only to the populations studied and reflect the characteristics of those patients.


Evidence in Special Patient Populations

Research has also examined the use of the medicine in certain special populations. Randomized Controlled Trials (RCTs) were conducted specifically on children and adolescents aged 10 years and older with Type 2 Diabetes. Studies monitored changes in blood sugar markers over trial periods up to one year or more. Research suggests that observed patterns may vary, and some studies indicate findings that were not sustained for the entire follow-up period.


Gaps and Areas of Research Uncertainty

Despite its history of use, research still highlights areas where data are less defined. Follow-up durations were limited in many initial regulatory trials for blood sugar marker shifts, and long-term effects on sustained patterns are not fully established in a general adult population. The primary evidence used to characterize long-term health outcomes is derived from the specific overweight subgroup of a single large trial; therefore, results apply only to the populations studied, and comparative evidence for other adult populations is lacking.

Frequently Asked Questions (FAQ)

Common questions about Glucofage (FAQ)


Q: Can Glucofage cause stomach issues or digestive problems?

A: Official product information states that common gastrointestinal side effects may include diarrhea, nausea, vomiting, and abdominal bloating. These effects are often most noticeable when first starting the medication. These symptoms often lessen as the body adjusts to the drug.

Q: Is it true that Glucofage can cause Vitamin B12 deficiency?

A: According to regulatory documents, the long-term use of Glucofage may be associated with a decrease in the body's Vitamin B12 levels. For this reason, official safety information recommends routine monitoring of Vitamin B12 status and blood counts for patients on this treatment.

Q: Is Glucofage safe to use long-term?

A: Glucofage is officially indicated for the management of type 2 diabetes mellitus, which is a chronic, ongoing condition. This means the medication is often used for the long-term management of the condition.

Q: Does Glucofage cause weight loss or weight gain?

A: Studies and official information indicate that Glucofage is generally associated with a stable body weight or, in some cases, modest weight loss. This observation is often noted when compared to other types of diabetes medications that can be associated with weight gain.

Q: How quickly does Glucofage start working?

A: The drug's concentration in the bloodstream typically stabilizes within 24 to 48 hours. However, the full therapeutic effect—the improvement in blood glucose control—is a gradual process that may take up to two to three months to fully manifest.

Q: Is Glucofage approved for use during pregnancy?

A: Regulatory data on the use of Glucofage during pregnancy is limited. The decision to use the medication requires assessing the drug's possible risks against the well-documented risks to both mother and fetus from uncontrolled high blood sugar.

Q: Is the effectiveness of Glucofage influenced by ethnicity or age?

A: Official prescribing information indicates that the drug's clearance (how the body eliminates it) may be decreased in elderly individuals. For this reason, regulatory documents indicate kidney function should be assessed more frequently in older adult populations.

Q: Does Glucofage interact with common pain relievers like ibuprofen?

A: Glucofage can be affected by other medicines that reduce its clearance through the kidneys. Because of this, official guidance advises informing a healthcare professional of all concurrent medications, including common pain relievers.

Q: What happens if I forget to take Glucofage one day?

A: Official prescribing information typically provides guidance on how to manage a missed dose. This guidance typically instructs patients to refer to their prescribed schedule, often by skipping the forgotten dose and resuming the regular timing.

Q: What happens if Glucofage is used past its expiration date?

A: Regulatory guidance from the FDA advises against using any medication, including Glucofage, past its expiration date. This is due to the potential for the medicine to lose potency or change in effectiveness over time.

Q: Can Glucofage affect my blood sugar levels too much?

A: Glucofage alone does not commonly cause hypoglycemia (very low blood sugar). However, official safety information describes the hypoglycemia (very low blood sugar) potential is increased when the medication is used in combination with other blood sugar-lowering medicines, such as insulin or insulin-secretagogue drugs.

Q: Is Glucofage a controlled substance?

A: Glucofage is not classified as a controlled substance under the Controlled Substances Act (CSA) in the United States. It is regulated as a standard prescription-only medicine.

Q: Can taking Glucofage affect the results of lab tests?

A: Official safety information indicates that Glucofage can interfere with some lab measurements of Vitamin B12 levels. Additionally, the serious side effect of lactic acidosis is defined by certain lab abnormalities, such as elevated blood lactate levels.

Q: How long can Glucofage stay in my system?

A: Pharmacokinetic studies indicate that the drug has a plasma elimination half-life of approximately 6.2 hours, and a longer whole-blood half-life of around 17.6 hours. These measurements describe the rate at which the medication is naturally cleared from the body.

Q: If I am taking Glucofage, can I still take herbal supplements?

A: Because herbal supplements are not tested or regulated in the same way as prescription drugs, their interaction potential is often unknown. Regulatory guidance emphasizes the importance of a healthcare professional being informed of all supplements and over-the-counter products being taken.

Q: Does Glucofage affect my liver function?

A: Glucofage is officially contraindicated, or should not be used, in patients who have existing hepatic impairment (liver problems). Official warnings state that liver impairment is considered a risk factor for developing the serious side effect of lactic acidosis.

Q: What official health bodies have approved Glucofage?

A: Glucofage (metformin) is a widely recognized drug that has been approved and is regulated by various official health bodies globally. In the United States, this includes the U.S. Food and Drug Administration (FDA).

Q: Does Glucofage have a 'black box warning'?

A: Yes, the official prescribing information contains a Boxed Warning, often referred to as a "black box warning." This alerts the user and physician to the potential for a rare, but serious, metabolic complication called lactic acidosis.

Q: How often do people need follow-up blood tests when taking Glucofage?

A: Monitoring of kidney function (eGFR) is required at least annually, according to official dosing guidelines. Additionally, monitoring of Vitamin B12 levels and hematological parameters (blood counts) is also recommended at least once a year or every two to three years.

Q: Can Glucofage affect sleep patterns?

A: Official safety information indicates that somnolence, which is unusual or severe sleepiness, is a non-specific symptom associated with the serious side effect of lactic acidosis. Severe fatigue or unusual sleepiness are symptoms associated with the condition and should be discussed with a healthcare professional.

Q: Is Glucofage a generic medicine, or is it only available as a brand?

A: Glucofage (metformin) is available in both the original brand name tablet and as multiple generic versions. These generic formulations are approved by the FDA and contain the same active ingredient.

Q: Does Glucofage treat the cause of diabetes or just the symptoms?

A: Glucofage is categorized as an antihyperglycemic agent. Its function is to improve glucose tolerance and lower elevated blood sugar levels, thereby managing the symptoms associated with high blood sugar.

How should Glucofage be stored and disposed of?

How to Store and Dispose of Glucofage?

Official Storage Requirements

Glucofage (metformin hydrochloride) tablets must be stored at Controlled Room Temperature, defined as 20° to 25°C (68° to 77°F). The medication must be kept out of the reach and sight of children.

The container must be kept tightly closed, stored in the container it came in, and protected from excessive moisture and light.


Disposal Instructions

Unused or expired Glucofage should be disposed of using a drug take-back program or mail-back envelope. If those options are unavailable, the medicine must be mixed with an unappealing substance (such as dirt or coffee grounds) and sealed in a plastic bag before being placed in the trash. The tablets must not be crushed during this process. Glucofage is not on the list of medicines recommended for flushing down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Glucofage found in:

A-Z Index: